| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
Revenue  | 2,337 | 2,665 | 2,960 | 3,416 | 3,792 | 4,208 | 4,391 | 4,997 | 5,503 | 6,097 | 6,524 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,337 | 3,389 | 3,832 | 4,143 | 4,396 | 4,648 |
| EBITDA | 360 | 415 | 455 | 642 | 718 | 871 | 1,002 | 1,165 | 1,360 | 1,701 | 1,876 |
| Operating Profit % | 13 % | 14 % | 14 % | 16 % | 16 % | 18 % | 21 % | 22 % | 23 % | 25 % | 26 % |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 |
| Interest | 1 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 10 |
| Profit Before Tax | 344 | 398 | 437 | 622 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,794 |
| Tax | 115 | 143 | 160 | 220 | 249 | 210 | 235 | 281 | 324 | 417 | 451 |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,335 |
| EPS in ₹ | 107.75 | 120.12 | 130.19 | 188.81 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 628.00 |
Abbott
31,101.85
+29.55
(0.10%)
Market Cap
66,026.50 Cr
EPS
565.30
PE Ratio
49.49
Dividend Yield
1.32 %
Industry
Healthcare52 Week High
31,898.95
52 Week Low
25,200.00
PB Ratio
18.76
Debt to Equity
0.03
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
10.80 %
Net Income Growth
26.52 %
Cash Flow Change
35.75 %
ROE
9.07 %
ROCE
9.92 %
EBITDA Margin (Avg.)
12.91 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 |
| Fixed Assets | 96 | 109 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 |
| Current Assets | 1,226 | 1,451 | 1,893 | 2,266 | 2,761 | 3,205 | 3,487 | 3,853 | 3,025 | 3,246 |
| Capital Work in Progress | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,953 | 4,315 | 4,958 |
| Total Liabilities | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 |
| Current Liabilities | 397 | 382 | 632 | 668 | 857 | 891 | 1,031 | 1,203 | 1,206 | 1,343 |
| Non Current Liabilities | 39 | 39 | 47 | 55 | 75 | 224 | 207 | 201 | 161 | 152 |
| Total Equity | 938 | 1,196 | 1,387 | 1,693 | 2,009 | 2,432 | 2,602 | 2,820 | 3,189 | 3,699 |
| Reserve & Surplus | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 |
| Share Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 |
| Investing Activities | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 |
| Operating Activities | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 |
| Financing Activities | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.18 % | 0.18 % | 0.18 % | 0.16 % | 0.16 % |
| DIIs | 4.60 % | 5.80 % | 4.30 % | 4.20 % | 4.96 % | 5.24 % | 7.73 % | 8.39 % | 8.62 % | 8.67 % | 8.71 % | 8.74 % | 8.91 % | 8.81 % | 8.99 % | 9.01 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.15 % | 15.83 % | 15.60 % | 15.81 % | 15.15 % | 14.72 % | 14.60 % | 14.25 % | 14.07 % | 13.95 % | 13.89 % | 13.97 % | 13.80 % | 13.86 % | 13.65 % | 13.59 % |
| Others | 4.26 % | 3.38 % | 5.11 % | 5.01 % | 4.91 % | 5.06 % | 2.68 % | 2.37 % | 2.32 % | 2.39 % | 2.42 % | 2.13 % | 2.12 % | 2.16 % | 2.21 % | 2.25 % |
| No of Share Holders | 0 | 84,478 | 75,540 | 73,417 | 83,236 | 90,567 | 82,113 | 83,526 | 72,086 | 69,582 | 68,885 | 72,252 | 69,382 | 71,588 | 69,449 | 67,892 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 40 | 55 | 65 | 250 | 275 | 275 | 325 | 410 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.73 | 0.75 | 0.42 | 1.67 | 1.55 | 1.26 | 1.2 | 1.32 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Closure of Trading Window
Rumour verification - Regulation 30(11)
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
Announcement under Regulation 30 (LODR)-Change in Management
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Newspaper Publication
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024
Board Meeting Outcome for Outcome Of Board Meeting
Announcement under Regulation 30 (LODR)-Change in Management
Board Meeting Intimation for Intimation Of Board Meeting Scheduled On February 5 2025 For Considering Unaudited Financial Results For Quarter And Nine Months Ended December 31 2024.
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Change in Management
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Announcement under Regulation 30 (LODR)-Change in Management
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Resignation of Director
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Abbott Launches 14 Valent Pneumococcal Conjugate Vaccine (PCV-14) That Offers Broadest Protection For Children Against Pneumococcal Bacterial Infections.
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations, 2015.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India ( Listing Obligations And Disclosure Requirements), Regulations, 2015.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Newspaper Publication
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Related Party Transaction Statement For The Half Year Ended September 30, 2024
Announcement under Regulation 30 (LODR)-Change in Directorate
Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024
Board Meeting Outcome for Outcome Of Board Meeting
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Change in Management
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Closure of Trading Window
Announcement Under Regulation 30 (LODR)
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Resignation of Director
Announcement Under Regulation 30
Announcement under Regulation 30 (LODR)-Resignation of Director
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Technical Indicators
RSI(14)
Neutral 61.04
ATR(14)
Less Volatile 884.22
STOCH(9,6)
Neutral 56.80
STOCH RSI(14)
Neutral 47.94
MACD(12,26)
Bearish -23.57
ADX(14)
Weak Trend 14.82
UO(9)
Bearish 55.64
ROC(12)
Uptrend And Accelerating 0.38
WillR(14)
Neutral -30.25
About Abbott
Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic areas including Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health. The company is structured into four divisions: Primary Care, Specialty Care-Methabolics and Urology, Specialty Care-Neuroscience, and Hospital Care. Abbott India manufactures and markets a wide range of products including Brufen, Prothiaden, Thyronorm, Leptos, Digene, Cremaffin, Influvac, and many others. The company has expanded its product portfolio through launches, acquisitions, and partnerships over the years. Abbott India is engaged in research and development, conducting clinical studies and publishing in medical journals. The company has also been recognized for innovation in the pharmaceutical industry.
Website
Chairperson NameMunir Shaikh
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
